Business Context and Reporting Period
Company: Gilead Sciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2008
Business Overview: Gilead is a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapeutics for life-threatening diseases, primarily HIV, Hepatitis B, and fungal infections. Key products include Truvada, Atripla, Viread, Hepsera, and AmBisome.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2008 |
Six Months Ended June 30, 2008 |
|---|---|---|
| Total Revenues | $1,278,125 | $2,536,277 |
| Net Income | $442,828 | $938,955 |
| Diluted EPS | $0.46 | $0.97 |
| Operating Cash Flow | N/A | $1,003,412 |
| Cash & Cash Equivalents | $1,119,599 | $1,119,599 |
| Total Marketable Securities | $1,788,753 | $1,788,753 |
| Convertible Senior Notes (Current) | $1,300,000 | $1,300,000 |
| Product Gross Margin | 78.2% | 78.6% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 22% for the quarter and 22% for the six-month period compared to 2007. Product sales grew 34% (quarter) and 35% (six months), driven primarily by Truvada (+34%) and Atripla (+67%).
- Royalty Decline: Royalty revenues decreased 63% for the quarter and 49% for the six months, primarily due to lower Tamiflu sales by partner Roche following the fulfillment of pandemic stockpiling orders.
- Profitability: Net income increased 9% for the quarter and 15% for the six months. Operating income rose 12% (quarter) and 16% (six months).
- Balance Sheet Shift: $1.3 billion in convertible senior notes were reclassified from long-term to current liabilities because the stock price met conversion criteria. Working capital decreased by $1.07 billion due to this reclassification and increased accounts payable.
- Stock Repurchases: The company repurchased $966 million of common stock during the first six months of 2008, including a $500 million accelerated share repurchase agreement.
Guidance, Outlook, and Risks
- Outlook: Management expects total product sales to continue growing in 2008 due to expanded sales efforts and the launch of Atripla in additional European countries. However, product gross margins are expected to be slightly lower than 2007 due to the higher mix of Atripla sales (which include a zero-margin component).
- R&D Pipeline: Phase 3 trials for elvitegravir (HIV) and darusentan (hypertension) are ongoing. Phase 2 for a Hepatitis C candidate is anticipated to begin by the end of 2008.
- Accounting Changes: Adoption of FSP APB 14-1 (effective late 2008) is expected to materially impact financials, potentially increasing interest expense by approximately $26 million for the six months ended June 30, 2008 upon retrospective application.
- Key Risks:
- Tamiflu Volatility: Royalty income is highly dependent on Roche's Tamiflu sales, which are unpredictable and currently declining.
- Product Concentration: HIV products (Truvada, Atripla) accounted for 81% of total revenues in Q2 2008.
- Liquidity of Investments: $131.3 million of the investment portfolio consists of auction rate securities (Level 3) which have experienced failed auctions and lack of liquidity, though no impairment was recorded.
- Regulatory & Legal: Ongoing FDA investigations into CRO bioanalytical data and a pending appeal of a dismissed securities class action lawsuit.
Investor Verification Checklist
- Verify the sustainability of Atripla and Truvada sales growth rates given the high concentration of revenue in these two products.
- Monitor Roche's Tamiflu sales reports to assess the trajectory of royalty revenue declines.
- Review the status of the $131.3 million auction rate securities portfolio for potential liquidity constraints or future impairments.
- Assess the impact of the upcoming adoption of FSP APB 14-1 on future interest expense and net income.
- Track the progress of FDA reviews for aztreonam lysine (cystic fibrosis) and Viread (Hepatitis B) to evaluate future revenue diversification.